Diabetes Management App Is Now Commercially Available

Medtronic and its strategic technology partner, IBM Watson Health, announced commercial availability of the Sugar.IQ smart diabetes assistant, a first-of-its-kind intelligent app designed to simplify and improve daily diabetes management.

Sugar.IQ smart diabetes assistant leverages artificial intelligence (AI) and analytic technologies to continually analyze how an individual’s glucose level responds to their food intake, insulin dosages, daily routines, and other factors, such as information provided by the app user.

For example, are certain foods worsening the patient’s glucose control? Are there particular days or times where a person’s glucose goes high or low? With Sugar.IQ, people with diabetes can uncover patterns that affect their glucose levels which can help them make small adjustments throughout the day to help stay on track.

Medtronic and IBM Watson Health leveraged their combined expertise in diabetes, AI and analytics to develop the Sugar.IQ diabetes assistant. It reveals patterns that may be hard to see so that someone with diabetes gains meaningful, personalized insights.

These insights show how lifestyle choices, medications, and multiple daily injections impact diabetes management and the time spent with glucose in the target range. The app uses AI and advanced analytics to give users a full picture of their current levels and provides insights and individualized guidance in understanding and managing daily diabetes management decisions, so that people on multiple daily insulin injections have more freedom to enjoy life.